| Literature DB >> 34508595 |
Wen-Qiang Zheng1,2, Signe Vandal Pedersen3, Kyle Thompson4, Emanuele Bellacchio5, Courtney E French6, Benjamin Munro7, Toni S Pearson8, Julie Vogt9, Daria Diodato10, Tue Diemer11, Anja Ernst12, Rita Horvath7, Manali Chitre13, Jakob Ek3, Flemming Wibrand3, Dorothy K Grange14, Lucy Raymond6, Xiao-Long Zhou1, Robert W Taylor4, Elsebet Ostergaard3,15.
Abstract
TARS2 encodes human mitochondrial threonyl tRNA-synthetase that is responsible for generating mitochondrial Thr-tRNAThr and clearing mischarged Ser-tRNAThr during mitochondrial translation. Pathogenic variants in TARS2 have hitherto been reported in a pair of siblings and an unrelated patient with an early onset mitochondrial encephalomyopathy and a combined respiratory chain enzyme deficiency in muscle. We here report five additional unrelated patients with TARS2-related mitochondrial diseases, expanding the clinical phenotype to also include epilepsy, dystonia, hyperhidrosis and severe hearing impairment. In addition, we document seven novel TARS2 variants-one nonsense variant and six missense variants-that we demonstrate are pathogenic and causal of the disease presentation based on population frequency, homology modeling and functional studies that show the effects of the pathogenic variants on TARS2 stability and/or function.Entities:
Mesh:
Substances:
Year: 2022 PMID: 34508595 DOI: 10.1093/hmg/ddab257
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150